Equillium, Inc. (NasdaqCM: EQ)
Health Care · Biotechnology · US
$2.20
-4.76% today · +21.6% 1Y
Equillium, Inc. (NasdaqCM: EQ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $146.47M and employs 14 people.
Over the last twelve months the share price has gained 21.6%, trading between 0.76 and 3.54.
Tweenvest scores Equillium, Inc. across four factors: quality 37/100. Its strongest factor is quality.
EQ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $146.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.20
- Dividend yield
- —
- Beta (5Y)
- 1.81
- 52-week high
- $3.54
- 52-week low
- $0.76
- Avg volume (3M)
- —
- Shares outstanding
- 63.41M
- Employees
- 14
- Next earnings
- —
About Equillium, Inc.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
- ISIN
- US29446K1060
- Founded
- 2017
- Listed since
- Oct 12, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.